Cetuximab for the Treatment of Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR. METHODS: From December 2003 to August 2005, 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine, irinotecan, and oxaliplatin or had contraindications to treatment with these drugs underwent randomization to an initial dose of 400 mg of cetuximab per square meter of body-surface area followed by a weekly infusion of 250 mg per square meter plus best supportive care (287 patients) or best supportive care alone (285 patients). The primary end point was overall survival. RESULTS: In comparison with best supportive care alone, cetuximab treatment was associated with a significant improvement in overall survival (hazard ratio for death, 0.77; 95% confidence interval [CI], 0.64 to 0.92; P=0.005) and in progression-free survival (hazard ratio for disease progression or death, 0.68; 95% CI, 0.57 to 0.80; P<0.001). These benefits were robust after adjustment in a multivariable Cox proportional-hazards model. The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group assigned to supportive care alone. Partial responses occurred in 23 patients (8.0%) in the cetuximab group but in none in the group assigned to supportive care alone (P<0.001); the disease was stable in an additional 31.4% of patients assigned to cetuximab and in 10.9% of patients assigned to supportive care alone (P<0.001). Quality of life was better preserved in the cetuximab group, with less deterioration in physical function and global health status scores (both P<0.05). Cetuximab treatment was associated with a characteristic rash; a rash of grade 2 or higher was strongly associated with improved survival (hazard ratio for death, 0.33; 95% CI, 0.22 to 0.50; P<0.001). The incidence of any adverse event of grade 3 or higher was 78.5% in the cetuximab group and 59.1% in the group assigned to supportive care alone (P<0.001). CONCLUSIONS: Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed. (ClinicalTrials.gov number, NCT00079066 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cetuximab is a chimeric (mouse/human) monoclonal IgG1 antibody developed to bind the extracellular EGFR domain that blocks dimerization and ligand-induced signaling of the EGFR pathway [14].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
In the citing paper
“Patients who received cetuximab had a 6.1-month median survival compared with 4.6 months among individuals in the best supportive care group.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Research works printed but not linked: 3
- Mellstedt H, 2003, Drugs Today (Barc), 39, 1
- Eng C, 2007, J Clin Oncol, 25, 18s
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
Cited by
Items 401–500 of 1,001
Mechanisms underlying18F-fluorodeoxyglucose accumulation in colorectal cancer
Kawada, K., Iwamoto, M., & Sakai, Y. (2016) · World Journal of Radiology · doi:10.4329/wjr.v8.i11.880 · Cited by 72
Hutchinson, R. A., Adams, R., McArt, D. G., Salto‐Tellez, M., Jasani, B., & Hamilton, P. W. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0531-z · Cited by 60
Erben, P., Ströbel, P., Horisberger, K., Popa, J., Bohn, B., Hanfstein, B., Kähler, G. F. B. A., Kienle, P., Post, S., Wenz, F. K., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.043 · Cited by 55
Bachet, J., Peuvrel, L., Bachmeyer, C., Reguiaï, Z., Gourraud, P., Bouché, O., Ychou, M., Bensadoun, R., Dréno, B., & André, T. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0365 · Cited by 56
Ishiguro, M., Watanabe, T., Yamaguchi, K., Satoh, T., Ito, H., Seriu, T., Sakata, Y., & Sugihara, K. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys005 · Cited by 58
Diao, Y., Qian, J., Liu, Y., Zhou, Y., Yan, W., Ma, H., Wang, X., Luo, R., Wagner, A. K., Sun, J., et al. (2019) · Journal of Global Health · doi:10.7189/jogh.09.020603 · Cited by 56
Rose, J. S., Serna, D. S., Martin, L. K., Li, X., Weatherby, L. M., Abdel‐Misih, S., Zhao, W., & Bekaii‐Saab, T. (2012) · Cancer · doi:10.1002/cncr.27666 · Cited by 53
Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches
Strickler, J. H., Wu, C. S.-Y., & Bekaii‐Saab, T. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.006 · Cited by 58
Targeting the RAS-dependent chemoresistance: The Warburg connection
Serna-Blasco, R., Sanz-Álvarez, M., Aguilera, Ó., & García-Foncillas, J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.016 · Cited by 52
You, B., & Chen, E. X. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010395940 · Cited by 57
A comparability study of 5 commercial KRAS tests
Oliner, K., Juan, T., Suggs, S., Wolf, M., Sarosi, I., Freeman, D. J., Gyuris, T., Baron, W., Bakker, A., Parker, A., et al. (2010) · Diagnostic Pathology · doi:10.1186/1746-1596-5-23 · Cited by 52
Herfs, M. F., Roncarati, P., Koopmansch, B., Peulen, O., Bruyère, D., Lebeau, A., Hendrick, E., Hubert, P., Poncin, A., Penny, W., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0049-2 · Cited by 59
Kim, T. W., Peeters, M., Thomas, A., Gibbs, P., Hool, K., Zhang, J., Ang, A. L., Bach, B. A., & Price, T. J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3377 · Cited by 60
Self-citationThe importance of Ras in drug resistance in cancer
Healy, F. M., Prior, I. A., & MacEwan, D. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15420 · Cited by 53
Peeters, M., BALFOUR, J., & Arnold, D. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03717.x · Cited by 56
Additivity predicts the efficacy of most approved combination therapies for advanced cancer
Hwangbo, H., Patterson, S. C., Dai, A., Plana, D., & Palmer, A. C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00667-z · Cited by 70
Zeng, D., Guo, Y., White, A. G., Cai, Z., Modi, J., Ferdani, R., & Anderson, C. J. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500004m · Cited by 54
Chang, D. Z., Kumar, V. S., Ma, Y., Li, K., & Kopetz, S. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-18 · Cited by 59
Vickers, M. M., Karapetis, C. S., Tu, D., O’Callaghan, C. J., Price, T. J., Tebbutt, N. C., van Hazel, G., Shapiro, J. D., Pavlakis, N., Gibbs, P., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds577 · Cited by 55
Self-citationFajardo-Puerta, A. B., Mato Prado, M., Frampton, A. E., & Jiao, L. R. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203575 · Cited by 51
Salvatore, L., Aprile, G., Arnoldi, E., Aschele, C., Carnaghi, C., Cosimelli, M., Maiello, E., Normanno, N., Sciallero, S., Valvo, F., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2016-000147 · Cited by 53
Hendriks, D., Choi, G., de Bruyn, M., Wiersma, V. R., & Bremer, E. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2016.10.002 · Cited by 66
NFAT5 promotes oral squamous cell carcinoma progression in a hyperosmotic environment
Yoshimoto, S., Morita, H., Matsuda, M., Katakura, Y., Hirata, M., & Hashimoto, S. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-00486-1 · Cited by 55
“Some informative studies report the efficacy of EGFR-targeted therapies on cancer progression using EGFR tyrosine kinase inhibitors (TKIs) or EGFRneutralizing antibodies [2, 3].”
BackgroundLévi, F., Karaboué, A., Gorden, L. D., Innominato, P. F., Saffroy, R., Giacchetti, S., Hauteville, D., Guettier, C., Adam, R. A., & Bouchahda, M. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1327-8 · Cited by 54
“In these multicenter studies, median PFS was \2 months and median overall survival times were less than 7 months [5, 9].”
BackgroundResultSiena, S., Glynne‐Jones, R., Adenis, A., Thaler, J., Preusser, P., Aguilar, E. A., Aapro, M., Loos, A. H., Esser, R., & Wilke, H. (2010) · Cancer · doi:10.1002/cncr.24945 · Cited by 52
Options for metastatic colorectal cancer beyond the second line of treatment
Foubert, F., Matysiak‐Budnik, T., & Touchefeu, Y. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.07.002 · Cited by 54
Zhu, Q., Izumchenko, E., Aliper, A. M., Makarev, E., Paz, K., Buzdin, A. A., Zhavoronkov, A. A., & Sidransky, D. (2015) · Human Genome Variation · doi:10.1038/hgv.2015.9 · Cited by 50
Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
Tischer, B., Huber, R., Kraemer, M., & Lacouture, M. E. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3419-4 · Cited by 54
Glockzin, G., Zeman, F., Croner, R. S., Königsrainer, A., Pelz, J. O. W., Ströhlein, M. A., Rau, B., Arnold, D., Koller, M. T., Schlitt, H. J., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.07.011 · Cited by 50
Masuishi, T., Tsuji, A., Kotaka, M., Nakamura, M., Kochi, M., Takagane, A., Shimada, K., Denda, T., Segawa, Y., Tanioka, H., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01042-w · Cited by 53
Systemic cancer therapy: Evolution over the last 60 years
Dy, G. K., & Adjei, A. A. (2008) · Cancer · doi:10.1002/cncr.23651 · Cited by 65
Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents
Costa, A., Tejpar, S., Prenen, H., & Cutsem, E. V. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0200-y · Cited by 49
Marchiò, S., Soster, M., Cardaci, S., Muratore, A., Bartolini, A., Barone, V., Ribero, D., Monti, M., Bovino, P., Sun, J. D., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101164 · Cited by 52
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status
Modest, D. P., Stintzing, S., Laubender, R. P., Neumann, J. H. L., Jung, A., Giessen, C. A., Haas, M., Aubele, P., Schulz, C. U., Boeck, S. H., et al. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283493160 · Cited by 53
Correlation Between PET/CT Parameters and KRAS Expression in Colorectal Cancer
Chen, S.-W., Chiang, H.-C., Chen, W. T., Hsieh, T., Yen, K., Chiang, S., & Kao, C. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000481 · Cited by 55
Second-line systemic therapy for metastatic colorectal cancer
Mocellin, S., Baretta, Z., Figuls, M. R. I., Solà, I., Martín-Richard, M., Hallum, S., & Bonfill, X. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006875.pub3 · Cited by 50
Bonnetain, F., Borg, C., Adams, R., Ajani, J. A., Benson, A. B., Bleiberg, H., Chibaudel, B., Díaz‐Rubio, E., Douillard, J., Fuchs, C. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx191 · Cited by 58
Molecular Targets for the Treatment of Metastatic Colorectal Cancer
Cohen, R., Pudlarz, T., Delattre, J.-F., Colle, R., & André, T. (2020) · Cancers · doi:10.3390/cancers12092350 · Cited by 57
“ICIs are also evaluated in combination with adjuvant chemotherapy for stage III MSI/dMMR colon cancer patients—the ATOMIC trial (NCT02912559; FOLFOX +/− atezolizumab), and the POLEM trial (NCT03827044; 24 weeks of single agent fluoropyrimidine chemotherapy or 12 weeks of oxaliplatin-based chemotherapy +/− avelumab) [2…”
MethodTargeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
Grothey, A. F. (2008) · Biologics · doi:10.2147/btt.s1980 · Cited by 58
Perkins, G., Lièvre, A., Ramacci, C., Méatchi, T., de Reynies, A., Emile, J., Boige, V., Tomasic, G., Bachet, J., Bibeau, F., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25152 · Cited by 49
Iida, M., Brand, T. M., Campbell, D. A., Starr, M. M., Luthar, N., Traynor, A. M., & Wheeler, D. L. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24342 · Cited by 52
Lyberopoulou, A., Aravantinos, G., EFSTATHOPOULOS, E. P., Nikiteas, N. I., Bouziotis, P., Isaakidou, A., Papalois, A. E., Marinos, E., & Gazouli, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123902 · Cited by 52
Modest, D. P., Jung, A., Moosmann, N., Laubender, R. P., Giessen, C. A., Schulz, C. U., Haas, M., Neumann, J. H. L., Boeck, S. H., Kirchner, T., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26467 · Cited by 56
Tseng, J., Bryan, D. S., Poli, E. C., Sharma, M. R., Polite, B. N., & Turaga, K. K. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30336-4 · Cited by 49
Frampton, J. E. (2010) · Drugs · doi:10.2165/11205010-000000000-00000 · Cited by 48
Yu, I. S., & Cheung, W. Y. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/9450754 · Cited by 47
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Gonzalez, N. S., Ros, J., Baraibar, I., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · Cancers · doi:10.3390/cancers16020412 · Cited by 57
“In various settings, first-line chemotherapy in combination with cetuximab or panitumumab demonstrated improved progression-free survival (PFS), OS, and ORRs in RAS wild-type (wt) mCRC patients [10–19].”
BackgroundMezzapelle, R., Miglio, U., Rena, O., Paganotti, A., Allegrini, S., Antona, J., Molinari, F., Frattini, M., Monga, G., Alabiso, O., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.130 · Cited by 52
Kumar, R., Jain, K., Beeke, C., Price, T. J., Townsend, A. R., Padbury, R., Roder, D. M., Young, G. P., Richards, A. M., & Karapetis, C. S. (2012) · Cancer · doi:10.1002/cncr.27802 · Cited by 50
Self-citationBanck, M. S., & Grothey, A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0188 · Cited by 48
Freeman, K., Connock, M. J., Cummins, E., Gurung, T., Taylor‐Phillips, S., Court, R. A., Saunders, M. P., Clarke, A., & Sutcliffe, P. A. (2015) · Health Technology Assessment · doi:10.3310/hta19910 · Cited by 56
Anderson, M. G., Falls, H. D., Mitten, M. J., Oleksijew, A., Vaidya, K. S., Boghaert, E. R., Gao, W., Palma, J. P., Cao, D., Chia, P.-L., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0149 · Cited by 49
Rodrigues, J. G., Duarte, H. O., Gomes, C., Balmaña, M., Martins, Á. M., Hensbergen, P. J., de Ru, A. H., Lima, J. P., Albergaria, A., van Veelen, P. A., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00606-z · Cited by 52
Aprile, G., Zanon, E., Tuniz, F., Iaiza, E., Pauli, F. D., Pella, N., Pizzolitto, S., Buffoli, A., Piga, A., Škrap, M., et al. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0468-1 · Cited by 50
“In developed countries, colorectal carcinoma ranks Wrst for incidence among gastrointestinal malignancies ( Jemal et al. 2007 ).”
BackgroundWinder, T., Zhang, W., Yang, D., Ning, Y., Bohanes, P., Gerger, A., Wilson, P. M., Pohl, A., Mauro, D. J., Langer, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2092 · Cited by 46
Self-citationDetection of KRAS mutations in colorectal cancer by high-resolution melting analysis
Ma, E. S. K., Wong, C., Law, F. B. F., Chan, W.-K., & Siu, D. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.063677 · Cited by 51
“To further address this point, retrospective analysis of archival tumour blocks of randomised trials has been undertaken. The CO.17 trial is a randomised trial reporting that, in comparison with best supportive care alone, cetuximab treatment is associated with a significant improvement in overall and progression-free…”
Fakih, M., Groman, A. E., McMahon, J., Wilding, G. E., & Muindi, J. R. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1762-1 · Cited by 46
Huang, J., Nair, S., Mahoney, M. R., Nelson, G. D., Shields, A. F., Chan, E. W., Goldberg, R. M., Gill, S., Kahlenberg, M. S., Quesenberry, J. T., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.12.002 · Cited by 52
on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG), Tebbutt, N. C., Price, T. J., Ferraro, D. A., Wong, N., Veillard, A.-S., Hall, M., Sjoquist, K. M., Pavlakis, N., Strickland, A. H., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.440 · Cited by 47
Self-citationSuenaga, M., Mashima, T., Kawata, N., Wakatsuki, T., Horiike, Y., Matsusaka, S., Dan, S., Shinozaki, E., Seimiya, H., Mizunuma, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9187 · Cited by 49
Biomarker in Colorectal Cancer
Schirripa, M., & Lenz, H. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000190 · Cited by 49
Schuurhuizen, C. S. E. W., Braamse, A. M. J., Konings, I. R. H. M., Sprangers, M. A. G., Ket, J. C. F., Dekker, J., & Verheul, H. M. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw617 · Cited by 47
“In the other studies with more toxicity, global QOL was better in two [26, 38] and worse in the remaining three studies [32, 37, 40].”
BackgroundResultInfluentialRamirez, J. A. Z., Romagnoli, G. G., Falasco, B. F., Gorgulho, C. M., Fogolin, C., dos Santos, D. C., Araújo, J. P., Lotze, M. T., Ureshino, R. P., & Kaneno, R. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106495 · Cited by 48
“Conventional therapy for patients with CRC is based on total or partial colectomy, usually followed by neoadjuvant or adjuvant chemotherapy [3] with a fluoropyrimidine, oxaliplatin, irinotecan and/or taxanes [4] .”
Electrolyte disorders related to EGFR-targeting drugs
Izzedine, H., Bahleda, R., Khayat, D., Massard, C., Magné, N., Spano, J., & Soria, J. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.03.012 · Cited by 46
Cost-Effectiveness Analysis of KRAS Testing and Cetuximab as Last-Line Therapy for Colorectal Cancer
Shiroiwa, T., Motoo, Y., & Tsutani, K. (2010) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256395 · Cited by 52
Molecularly targeted drugs for metastatic colorectal cancer
Yang, H., CHENG, Y.-D., Chen, G., & Zhang, Z.-C. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s52485 · Cited by 51
Kalikaki, A., Politaki, H., Souglakos, J., Apostolaki, S., Papadimitraki, E., Georgoulia, N., Tzardi, M. N., Mavroudis, D., Georgoulias, V., & Voutsina, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104902 · Cited by 47
A view on EGFR-targeted therapies from the oncogene-addiction perspective
Pérez, R., Crombet, T., de León, J., & Moreno, E. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00053 · Cited by 50
Glockzin, G., Rochon, J., Arnold, D., Lang, S. A., Klebl, F. H., Zeman, F., Koller, M. T., Schlitt, H. J., & Piso, P. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-67 · Cited by 48
Eng, C. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0167 · Cited by 45
Rosenbaum, C. E. N. M., Verkooijen, H. M., Lam, M. G. E. H., Smits, M. L. J., Koopman, M., van Seeters, T., Vermoolen, M. A., & van den Bosch, M. A. A. J. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.119545 · Cited by 46
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
Wurz, G. T., Kao, C.-J., & DeGregorio, M. W. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015615514 · Cited by 53
“Panitumumab was most recently approved in 2014 as first-line treatment in combination with chemotherapy in KRAS wild-type, metastatic CRC following the results of phase III clinical trials showing a significant increase in PFS, an increase in OS [Douillard et al.”
ResultInfluentialMustafa, R. A., Wiercioch, W., Cheung, A., Prediger, B., Brożek, J., Bossuyt, P. M., Garg, A. X., Lelgemann, M., Bühler, D., & Schünemann, H. J. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.09.003 · Cited by 51
Zhou, Y., Zhang, J., Pu, D., Bi, F., Chen, Y., Liu, J., Li, Q., Gou, H., Wu, B., & Qiu, M. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000726 · Cited by 46
Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
Rawla, P., Barsouk, A. A., Hadjinicolaou, A. V., & Barsouk, A. (2019) · Medical Sciences · doi:10.3390/medsci7080083 · Cited by 52
“9 months) while preserving the quality of life standards as compared to best supportive care [77].”
BackgroundInoue, A., Deem, A. K., Kopetz, S., Heffernan, T. P., Draetta, G. F., & Carugo, A. (2019) · Cancers · doi:10.3390/cancers11091321 · Cited by 45
“Moreover, PDX models that responded to single-agent cetuximab had significantly higher EGFR copy number and higher EGFR expression, which is again similar to the findings observed in patients [120,122,123].”
ResultAsmis, T., Powell, E. D., Karapetis, C. S., Jonker, D. J., Tu, D., Jeffery, M., Pavlakis, N., Gibbs, P., Zhu, L., Dueck, D.-A., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq309 · Cited by 48
“ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; LDH, lactate dehydrogenase; CTC, Common Toxicity Criteria; BSC, best supportive care; UNL, upper limit of the normal range, as defined in [26].”
BackgroundInfluentialSelf-citationZafar, S. Y., Currow, D. C., & Abernethy, A. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7491 · Cited by 47
Shaham, S. H., Vij, P., & Tripathi, M. K. (2025) · Biomedicines · doi:10.3390/biomedicines13030642 · Cited by 54
Renal toxicity of anticancer agents targeting HER2 and EGFR
Cosmai, L., Gallieni, M. A., & Porta, C. (2015) · Journal of Nephrology · doi:10.1007/s40620-015-0226-9 · Cited by 45
Steele, M. L., Axtner, J., Happe, A., Kröz, M., Matthes, H., & Schad, F. (2014) · Integrative Cancer Therapies · doi:10.1177/1534735414563977 · Cited by 48
Trippett, T. M., Herzog, C. E., Whitlock, J. A., Wolff, J. E. A., Kuttesch, J. F., Bagatell, R., Hunger, S. P., Boklan, J., Smith, A., Arceci, R. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8975 · Cited by 46
Self-citationSaif, M. W., Kaley, K., Chu, E., & Copur, M. S. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.046 · Cited by 47
Ulivi, P., Capelli, L., Valgiusti, M., Zoli, W., Scarpi, E., Chiadini, E., Rosetti, P., Bravaccini, S., Calistri, D., Saragoni, L., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-87 · Cited by 47
Prognostic value of ERBB4 expression in patients with triple negative breast cancer
Kim, J.-Y., Jung, H. H., Do, I.-G., Bae, S., Lee, S. K., Kim, S. W., Lee, J. E., Nam, S. J., Ahn, J. S., Park, Y. H., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2195-3 · Cited by 44
Therapeutic Antibodies in Cancer Therapy
Gasser, M., & Waaga-Gasser, A. M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-32805-8_6 · Cited by 51
Hofheinz, R.-D., Segaert, S., Safont, M. J., Demonty, G., & Prenen, H. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.032 · Cited by 42
Yao, Y.-M. M., Donoho, G. P., Iversen, P. W., Zhang, Y., Van Horn, R. D., Forest, A., Novosiadly, R. D., Webster, Y. W., Ebert, P., Bray, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3250 · Cited by 44
The importance of greater speed in drug development for advanced malignancies
Stewart, D. J., Stewart, A. A., Wheatley‐Price, P., Batist, G., Kantarjian, H. M., Schiller, J. H., Clemons, M. J., Bradford, J., Gillespie, L., & Kurzrock, R. (2018) · Cancer Medicine · doi:10.1002/cam4.1454 · Cited by 49
Acute abdominal obstruction: Colon stent or emergency surgery? An evidence-based review
Ribeiro, I. B., de Moura, D. T. H., Thompson, C. C., & de Moura, E. G. H. (2019) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v11.i3.193 · Cited by 45
Nakadate, Y., Kodera, Y., Kitamura, Y., Shirasawa, S., Tachibana, T., Tamura, T., & Koizumi, F. (2014) · International Journal of Cancer · doi:10.1002/ijc.28550 · Cited by 43
Nishiofuku, H., Tanaka, T., Matsuoka, M., Otsuji, T., Anai, H., Sueyoshi, S., Inaba, Y., Koyama, F., Sho, M., Nakajima, Y., et al. (2012) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2012.09.010 · Cited by 45
Ouwerkerk, J., & Boers-Doets, C. B. (2010) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2010.03.004 · Cited by 47
“Cetuximab has been studied as monotherapy (Jonker et al., 2007; Karapetis et al., 2008; Saltz et al., 2004), as well as in combination with chemotherapy (Bokemeyer et al.”
BackgroundSantoro, A., Rimassa, L., Sobrero, A. F., Citterio, G., Sclafani, F., Carnaghi, C., Pessino, A. M., Caprioni, F., Andretta, V., Tronconi, M. C., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.012 · Cited by 46
Mita, A. C., Papadopoulos, K. P., de Jonge, M. J. A., Schwartz, G. H., Verweij, J., Mita, M. M., Ricart, A. D., Chu, Q. S.-C., Tolcher, A. W., Wood, L., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.332 · Cited by 46
Wang, H., Lu, J., Wang, L., Chen, S., He, K., Jiang, X., Jiang, W., & Teng, L. (2017) · BMC Cancer · doi:10.1186/s12885-017-3177-9 · Cited by 43
(2010) · Europe PMC (PubMed Central) · Cited by 53
Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers
Yang, Y.-C. S. H., Ko, P.-J., Pan, Y.-S., Lin, H., Whang‐Peng, J., Davis, P. J., & Wang, K. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00719-5 · Cited by 53
EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED THERAPIES FOR SOLID TUMOURS
den Eynde, M. V., Baurain, J. F., Mazzeo, F., & Machiels, J.-P. (2011) · Acta Clinica Belgica · doi:10.1179/acb.66.1.2062508 · Cited by 45
Silnitsky, S., Rubin, S. J. S., Zerihun, M., & Qvit, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417600 · Cited by 48
Metadata
- Authors
- Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., Tebbutt, N. C., van Hazel, G., Wierzbicki, R., Langer, C., & Moore, M. J.
- Affiliations
- University of Ottawa (CA)
- Flinders Medical Centre (AU)
- The University of Melbourne (AU)
- Queen's University (CA)
- Cross Cancer Institute (CA)
- Sunnybrook Health Science Centre (CA)
- St. Boniface Hospital (CA)
- Queen Elizabeth Hospital (AU)
- The University of Sydney (AU)
- Austin Health (AU)
- Lakeridge Health (CA)
- Bristol-Myers Squibb (United States) (US)
- Princess Margaret Cancer Centre (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2040-2048
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115790682
- Cited by
- 1,904
- References
- 20
- Citations by year
- 2026: 23 · 2025: 47 · 2024: 56 · 2023: 60 · 2022: 62 · 2021: 63 · 2020: 87 · 2019: 82 · 2018: 84 · 2017: 101 · 2016: 110 · 2015: 133 · 2014: 143 · 2013: 150 · 2012: 153
- FWCI
- 68.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- cetuximab, colorectal cancer, epidermal growth factor receptor, EGFR-positive tumors, monoclonal antibody therapy, best supportive care, overall survival, progression-free survival, rash, quality of life, adverse events, irinotecan, oxaliplatin, fluoropyrimidine
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Exanthema, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Colorectal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.